Wednesday, December 7, 2011

Bolero Isn't Just About Fashion Anymore

For certain women with metastatic breast cancer, a bolero is no longer a fashion accessory but great news about a potentially life-prolonging cancer treatment.          
Results of the international BOLERO-2 trial (Breast Cancer Trials of Oral Everolimus) released yesterday at the San Antonio Breast Cancer Symposium and discussed in a press briefing this morning show that the combination of everolimus (Afinitor/Novaris) and exemestane (Aromisin/Pfizer) represents a “new standard of care” in women with hormone resistant, metastatic breast cancer.  These women, whose cancer is fueled by the estrogen, have disease that has advanced despite previous treatment with endocrine and/or chemotherapy.
          This is good news from a number of angles:         
          1) Both are oral medications.
          2) The new strategy delivers a “smart bomb” that specifically interrupts the molecular pathways involved in drug resistance. It continues the evolution in treatment that digs deeper into the biological mechanisms of the cell with each new generation of medications.
          3) The everolimus/exemestane combination kept the cancer at bay for a median of 7.4 months compared to the 3.2 months for those who took exemestane alone with “modest addition of toxicity.”  Those side effects, higher in the group with the drug combination, include shortness of breath, hyperglycemia, mouth sores and fatigue.
On the American Cancer Society Blog Len Lichtenfeld, M.D. wrote, “This study suggests that researchers could indeed produce remarkable results by rationally designing a treatment approach based on science where the hormone resistance was turned off and allowed a different hormone therapy to effectively treat the disease.”
Rational design.  Elegant design.  You hear these phrases attached to the larger and more significant trials.  It’s the same principle as garbage in, garbage out.  BOLERO-2 was expected to be successful because it expanded naturally from one finding to the next. 
A drawback will be the cost.  In this excellent article by AP’s Marilyn Marchione a one-month supply of Novartis AG’s Afinitor, originally developed as an anti-rejection agent for organ transplants, is listed at $11,000 per month.  Another article in the Boston Globe listed the price as $7,000 per month.
You can listen to Gabriel Hortobagyi, M.D., director of the Multidiscliplinary Breast Cancer Research Program at the University of Texas MD Anderson Cancer Center, and lead investigator, discuss the trial here:
        This trial was funded by Novartis.


Beth L. Gainer said...


Thank you for such an informative, excellent posting. I'm livid that the drug is so darn expensive; it's just not fair.

Jody said...


It's awful that we have to think about the cost when something that has proven beneficial has been demonstrated. This is especially true in the case of hormone positive breast cancers, which represent about 75% of all the cases.

In fact between the two big trial advances announced this year - there was clear progress in both hormone positive and HER2+ cancers with Genetech's new Pertuzumab. This will (just a guess) be more than Everolimus but I haven't seen a cost announced on that one yet, only guesses.

Thanks for reading,

Patricia Parker said...

Thanks for sharing information about Bolero. It is worth to know about.
Nice sharing and keep posting.
cancer treatment center

DENICE said...

Thanks for sharing the information. I am a surgeon & work with Dr Susan Lim Singapore. She is the first surgeon in Asia who has transplant liver successfully. Anyone wants to know about her click here-